Retrophin Inc - Company & Market Research Reports

Retrophin is a biopharmaceutical company that is based in San Diego, California. The company’s leading pipeline assets are fosmetpantotenate (RE-024), is a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease. Its marketed products include Chenodal, Cholbam and Thiola. Retrophin was founded in 2011.

Focal Segmental Glomerulosclerosis (FSGS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - Product Thumbnail Image

Focal Segmental Glomerulosclerosis (FSGS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • Report
  • 85 Pages
From
IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments - Product Thumbnail Image

IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

  • Report
  • 97 Pages
From
2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report

  • Report
  • 50 Pages
From
Infantile Spasm (West Syndrome) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Infantile Spasm (West Syndrome) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 55 Pages
From
Thiola 2017 U.S. Promotional Audit Report - Product Thumbnail Image

Thiola 2017 U.S. Promotional Audit Report

  • Report
  • 26 Pages
From
Cholbam 2017 U.S. Promotional Audit Report - Product Thumbnail Image

Cholbam 2017 U.S. Promotional Audit Report

  • Report
  • 21 Pages
From
Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market - Segmented by Disease Type, Disease Management, and Geography - Growth, Trends, and Forecast (2018 - 2023) - Product Thumbnail Image

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market - Segmented by Disease Type, Disease Management, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • Report
  • 121 Pages
From
2018 Gastritis (stomach inflammation) Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Gastritis (stomach inflammation) Drug Development- Pipeline Analysis Report

  • Report
  • 40 Pages
From
Glomerulonephritis - Pipeline Review, H2 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 212 Pages
From
Glomerulonephritis - Pipeline Review, H1 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 201 Pages
From
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016 - Product Thumbnail Image

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

  • Drug Pipelines
  • 58 Pages
From
Global Infantile Spasms Therapeutics Market 2017-2021 - Product Thumbnail Image

Global Infantile Spasms Therapeutics Market 2017-2021

  • Report
  • 73 Pages
From
Glomerulonephritis - Pipeline Insights, 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Insights, 2018

  • Drug Pipelines
  • 102 Pages
From
Autism Spectrum Disorder Treatment Market: By Autism Type; By Treatment Approach & By Geography - Forecast 2016-2021 - Product Thumbnail Image

Autism Spectrum Disorder Treatment Market: By Autism Type; By Treatment Approach & By Geography - Forecast 2016-2021

  • Report
  • 132 Pages
From
Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018 - Product Thumbnail Image

Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018

  • Drug Pipelines
  • 147 Pages
From
Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016 - Product Thumbnail Image

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

  • Drug Pipelines
  • 63 Pages
From
2018 Post Operative Nausea And Vomiting Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Post Operative Nausea And Vomiting Drug Development- Pipeline Analysis Report

  • Report
  • 40 Pages
From
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016 - Product Thumbnail Image

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016

  • Drug Pipelines
  • 49 Pages
From
Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016 - Product Thumbnail Image

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016

  • Drug Pipelines
  • 60 Pages
From
Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016 - Product Thumbnail Image

Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016

  • Drug Pipelines
  • 65 Pages
From
Loading Indicator
adroll